Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PROCEADE PanTumor: A Phase 1b/2, Multicenter, Open-Label Study of Anti-CEACAM5 Antibody-Drug Conjugate M9140 in Participants With Advanced Solid Tumors (Master Protocol)

NCT06710132 is registered in ClinicalTrials.gov with EMD Serono Research & Development Institute, Inc. as lead sponsor.

NCT NCT06710132
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06710132 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PROCEADE PanTumor: A Phase 1b/2, Multicenter, Open-Label Study of Anti-CEACAM5 Antibody-Drug Conjugate M9140 in Participants With Advanced Solid Tumors (Master Protocol)
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
January 29, 2025
Completion date
December 23, 2027
Enrollment
184 (actual)
Sites
81

Conditions

As the registry lists them; a condition with its own page is linked.

gastric cancer, non-small cell lung cancer (nsclc), pancreatic cancer, pancreatic ductal adenocarcinoma (pdac), solid tumors